198 related articles for article (PubMed ID: 34072463)
1. Detecting Variants in the NBN Gene While Testing for Hereditary Breast Cancer: What to Do Next?
Zuntini R; Bonora E; Pradella LM; Amato LB; Vidone M; De Fanti S; Catucci I; Cortesi L; Medici V; Ferrari S; Gasparre G; Peterlongo P; Sazzini M; Turchetti D
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072463
[TBL] [Abstract][Full Text] [Related]
2. A case of contralateral breast cancer and skin cancer associated with NBN heterozygous pathogenic variant c.698_701delAACA.
Gass J; Jackson J; Macklin S; Blackburn P; Hines S; Atwal PS
Fam Cancer; 2017 Oct; 16(4):551-553. PubMed ID: 28374160
[TBL] [Abstract][Full Text] [Related]
3. Variations in the NBN/NBS1 gene and the risk of breast cancer in non-BRCA1/2 French Canadian families with high risk of breast cancer.
Desjardins S; Beauparlant JC; Labrie Y; Ouellette G; Durocher F;
BMC Cancer; 2009 Jun; 9():181. PubMed ID: 19523210
[TBL] [Abstract][Full Text] [Related]
4. Candidate gene analysis of BRCA1/2 mutation-negative high-risk Russian breast cancer patients.
Sokolenko AP; Preobrazhenskaya EV; Aleksakhina SN; Iyevleva AG; Mitiushkina NV; Zaitseva OA; Yatsuk OS; Tiurin VI; Strelkova TN; Togo AV; Imyanitov EN
Cancer Lett; 2015 Apr; 359(2):259-61. PubMed ID: 25619955
[TBL] [Abstract][Full Text] [Related]
5. Allelic modification of breast cancer risk in women with an NBN mutation.
Rusak B; Kluźniak W; Wokołorczyk D; Stempa K; Kashyap A; Rudnicka H; Gronwald J; Huzarski T; Dębniak T; Jakubowska A; Szwiec M; Akbari MR; Narod SA; Lubiński J; Cybulski C;
Breast Cancer Res Treat; 2019 Nov; 178(2):427-431. PubMed ID: 31410679
[TBL] [Abstract][Full Text] [Related]
6. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer.
Weitzel JN; Neuhausen SL; Adamson A; Tao S; Ricker C; Maoz A; Rosenblatt M; Nehoray B; Sand S; Steele L; Unzeitig G; Feldman N; Blanco AM; Hu D; Huntsman S; Castillo D; Haiman C; Slavin T; Ziv E
Cancer; 2019 Aug; 125(16):2829-2836. PubMed ID: 31206626
[TBL] [Abstract][Full Text] [Related]
7. Multigene panel testing in unselected Israeli breast cancer cases: mutational spectrum and use of BRCA1/2 mutation prediction algorithms.
Bernstein-Molho R; Singer A; Laitman Y; Netzer I; Zalmanoviz S; Friedman E
Breast Cancer Res Treat; 2019 Jul; 176(1):165-170. PubMed ID: 30980208
[TBL] [Abstract][Full Text] [Related]
8. Association of PALB2 sequence variants with the risk of familial and early-onset breast cancer in a South-American population.
Leyton Y; Gonzalez-Hormazabal P; Blanco R; Bravo T; Fernandez-Ramires R; Morales S; Landeros N; Reyes JM; Peralta O; Tapia JC; Gomez F; Waugh E; Ibañez G; Pakomio J; Grau G; Jara L
BMC Cancer; 2015 Jan; 15():30. PubMed ID: 25636233
[TBL] [Abstract][Full Text] [Related]
9. DNA repair functional analyses of NBN hypomorphic variants associated with NBN-related infertility.
Fiévet A; Bellanger D; Zahed L; Burglen L; Derrien AC; Dubois d'Enghien C; Lespinasse J; Parfait B; Pedespan JM; Rieunier G; Stoppa-Lyonnet D; Stern MH
Hum Mutat; 2020 Mar; 41(3):608-618. PubMed ID: 31729086
[TBL] [Abstract][Full Text] [Related]
10. Identification of a novel NBN truncating mutation in a family with hereditary prostate cancer.
Zuhlke KA; Johnson AM; Okoth LA; Stoffel EM; Robbins CM; Tembe WA; Salinas CA; Zheng SL; Xu J; Carpten JD; Lange EM; Isaacs WB; Cooney KA
Fam Cancer; 2012 Dec; 11(4):595-600. PubMed ID: 22864661
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of hereditary cancer panel testing: Impact of PALB2, ATM, CHEK2, NBN, BRIP1, RAD51C, and RAD51D results on patient management and adherence to provider recommendations.
Vysotskaia V; Kaseniit KE; Bucheit L; Ready K; Price K; Johansen Taber K
Cancer; 2020 Feb; 126(3):549-558. PubMed ID: 31682005
[TBL] [Abstract][Full Text] [Related]
12. Identification of a rare germline NBN gene mutation by whole exome sequencing in a lung-cancer survivor from a large family with various types of cancer.
Marafie MJ; Dashti M; Al-Mulla F
Fam Cancer; 2017 Jul; 16(3):389-394. PubMed ID: 27844240
[TBL] [Abstract][Full Text] [Related]
13. [The clinical importance of a genetic analysis of moderate-risk cancer susceptibility genes in breast and other cancer patients from the Czech Republic].
Pohlreich P; Kleibl Z; Kleiblová P; Janatová M; Soukupová J; Macháčková E; Házová J; Vašíčková P; Sťahlová Hrabincová E; Navrátilová M; Svoboda M; Foretová L
Klin Onkol; 2012; 25 Suppl():S59-66. PubMed ID: 22920209
[TBL] [Abstract][Full Text] [Related]
14. Genetic Variation in the 3'-Untranslated Region of NBN Gene Is Associated with Gastric Cancer Risk in a Chinese Population.
Sun P; Du J; Zhu X; Ren C; Xie L; Dai N; Gu Y; Yan C; Dai J; Ma H; Jiang Y; Chen J; Hu Z; Shen H; Wu H; Jin G
PLoS One; 2015; 10(9):e0139059. PubMed ID: 26402912
[TBL] [Abstract][Full Text] [Related]
15. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
16. Familial breast cancer and DNA repair genes: Insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
Girard E; Eon-Marchais S; Olaso R; Renault AL; Damiola F; Dondon MG; Barjhoux L; Goidin D; Meyer V; Le Gal D; Beauvallet J; Mebirouk N; Lonjou C; Coignard J; Marcou M; Cavaciuti E; Baulard C; Bihoreau MT; Cohen-Haguenauer O; Leroux D; Penet C; Fert-Ferrer S; Colas C; Frebourg T; Eisinger F; Adenis C; Fajac A; Gladieff L; Tinat J; Floquet A; Chiesa J; Giraud S; Mortemousque I; Soubrier F; Audebert-Bellanger S; Limacher JM; Lasset C; Lejeune-Dumoulin S; Dreyfus H; Bignon YJ; Longy M; Pujol P; Venat-Bouvet L; Bonadona V; Berthet P; Luporsi E; Maugard CM; Noguès C; Delnatte C; Fricker JP; Gesta P; Faivre L; Lortholary A; Buecher B; Caron O; Gauthier-Villars M; Coupier I; Servant N; Boland A; Mazoyer S; Deleuze JF; Stoppa-Lyonnet D; Andrieu N; Lesueur F
Int J Cancer; 2019 Apr; 144(8):1962-1974. PubMed ID: 30303537
[TBL] [Abstract][Full Text] [Related]
17. Whole-exome sequencing of Finnish hereditary breast cancer families.
Määttä K; Rantapero T; Lindström A; Nykter M; Kankuri-Tammilehto M; Laasanen SL; Schleutker J
Eur J Hum Genet; 2016 Jan; 25(1):85-93. PubMed ID: 27782108
[TBL] [Abstract][Full Text] [Related]
18. Inherited NBN Mutations and Prostate Cancer Risk and Survival.
Rusak B; Kluźniak W; Wokołorczykv D; Stempa K; Kashyap A; Gronwald J; Huzarski T; Dębniak T; Jakubowska A; Masojć B; Akbari MR; Narodv SA; Lubiński J; Cybulski C
Cancer Res Treat; 2019 Jul; 51(3):1180-1187. PubMed ID: 30590007
[TBL] [Abstract][Full Text] [Related]
19. Clinically Significant Unclassified Variants in
Yoon KA; Park B; Lee BI; Yang MJ; Kong SY; Lee ES
Cancer Res Treat; 2017 Jul; 49(3):627-634. PubMed ID: 27658390
[TBL] [Abstract][Full Text] [Related]
20.
Concolino P; Gelli G; Rizza R; Costella A; Scambia G; Capoluongo E
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31336956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
